Telehealth after the pandemic: Will the inverse care law apply? (Commentary)
- PMID: 34521596
- PMCID: PMC8433501
- DOI: 10.1016/j.jcf.2021.08.023
Telehealth after the pandemic: Will the inverse care law apply? (Commentary)
Abstract
The COVID-19 pandemic has accelerated the use of telehealth within the cystic fibrosis (CF) community to deliver CF care. The article by Solomon and colleagues exploring the patient and family experiences of telehealth care delivery, as part of the CF chronic care model in the US, is therefore timely. In this commentary, we discuss how the US experience of telehealth care compares with reports from CF centres in other parts of the world. We highlight the potential challenges, including whether the inverse care law will apply in this new era of CF telehealth.
Keywords: COVID-19; Cystic fibrosis; Telehealth; Telemedicine.
Copyright © 2021. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest R.C has no conflicts of interest. Outside the submitted work, A.S reports grants from Vertex and reports speaker honoraria and expenses from TEVA and Vertex. A.S reports membership of the US CF Foundation therapeutic development network data safety monitoring board. A.R. Smyth has a patent “Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof” issued.
Comment on
-
Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic.J Cyst Fibros. 2021 Dec;20 Suppl 3:41-46. doi: 10.1016/j.jcf.2021.09.005. J Cyst Fibros. 2021. PMID: 34930542 Free PMC article.
References
-
- World Health Organisation. Statement on the second meeting of the international health regulations (2005) emergency committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020. Available from: https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting...).
-
- Public Health England. Guidance on protecting people who are clinically extremely vulnerable from COVID-19. 2021. Available from: https://www.gov.uk/government/publications/guidance-on-shielding-and-pro....
-
- Castellani C., Duff A.J., Bell S.C., Heijerman H.G., Munck A., Ratjen F., et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153–178. - PubMed
-
- Calthorpe R.J., Smith S., Gathercole K., Smyth A.R. Using digital technology for home monitoring, adherence and self-management in cystic fibrosis: a state-of-the-art review. Thorax. 2020;75(1):72. - PubMed
-
- Davies G., Rowbotham N.J., Smith S., Elliot Z.C., Gathercole K., Rayner O., et al. Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials. J Cyst Fibros. 2020;19(3):499–502. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
